Barclays’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Barclays’s Portfolio WX Stock Details WX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-54,500	Closed	-$2.34M	–	7184
2015 Q3	$2.34M	Buy	54,500 +12,500	+30%	+$527K	﹤0.01%	1993
2015 Q2	$1.76M	Buy	42,000 +40,600	+2,900%	+$1.71M	﹤0.01%	2332
2015 Q1	$53K	Buy	1,400 +500	+56%	+$19.3K	﹤0.01%	5243
2014 Q4	$30K	Buy	900 +100	+13%	+$3.53K	﹤0.01%	6077
2014 Q3	$28K	Sell	800 -1,900	-70%	-$65.1K	﹤0.01%	6282
2014 Q2	$86K	Buy	2,700 +2,400	+800%	+$82.1K	﹤0.01%	5540
2014 Q1	$11K	Sell	300 -300	-50%	-$11K	﹤0.01%	6906
2013 Q4	$23K	Hold	600	–	–	﹤0.01%	6644
2013 Q3	$16K	Sell	600 -700	-54%	-$16.6K	﹤0.01%	6633
2013 Q2	$27K	Buy	+1,300	New	+$25.4K	﹤0.01%	6694

Other funds holding WX

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

CCS

Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Barclays's WX Position: Q4 2015 in Review

Barclays sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 149,583 shares — an estimated $6.43M sold.

Barclays first reported a position in WX in Q2 2013 and held it in 10 quarters. The position peaked at $6.68M in Q1 2015. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

Barclays reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
Barclays sold 149,583 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $6.43M.
Barclays first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 10 quarters.
Barclays's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $6.68M in Q1 2015.
2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Barclays's 13F filing for Q4 2015, filed 12 Feb 2016.